Evidence map›Paper›PMID 33910584›Full record

ArticleJournal of translational medicine2021

Impact of immediate cryopreservation on the establishment of patient derived xenografts from head and neck cancer patients.

Lindsey Abel, Arda Durmaz, Rong Hu, Colin Longhurst, Andrew M Baschnagel, Deric Wheeler, Jacob G Scott, Randall J Kimple

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lindsey AbelDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, 3107 WIMR, Madison, WI, 53705-2275, USA.
Arda DurmazDepartments of Translational Hematology and Oncology Research and Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA.
Rong HuDepartment of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Colin LonghurstDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Andrew M BaschnagelDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, 3107 WIMR, Madison, WI, 53705-2275, USA.
Deric WheelerDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, 3107 WIMR, Madison, WI, 53705-2275, USA.
Jacob G ScottDepartments of Translational Hematology and Oncology Research and Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA.
Randall J KimpleDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, 3107 WIMR, Madison, WI, 53705-2275, USA. rkimple@humonc.wisc.edu.ORCID 0000-0001-8336-8000
University of Wisconsin–Madison · USCleveland Clinic · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI YU, MENGGANG · 2016 to 2020
$10.8M
NCI NIH HHS P30 CA014520NIDCR NIH HHS P50 DE026787
6 · The paper itself

Abstract

backgroundPatient-derived xenografts established from human cancers are important tools for investigating novel anti-cancer therapies. Establishing PDXs requires a significant investment and many PDXs may be used infrequently due to their similarity to existing models, their growth rate, or the lack of relevant mutations. We performed this study to determine whether we could efficiently establish PDXs after cryopreservation to allow molecular profiling to be completed prior to implanting the human cancer.

methodsFresh tumor was split with half used to establish a PDX immediately and half cryopreserved for later implantation. Resulting tumors were assessed histologically and tumors established from fresh or cryopreserved tissues compared as to the growth rate, extent of tumor necrosis, mitotic activity, keratinization, and grade. All PDXs were subjected to short tandem repeat testing to confirm identity and assess similarity between methods.

resultsTumor growth was seen in 70% of implanted cases. No growth in either condition was seen in 30% of tumors. One developed a SCC from the immediate implant but a lymphoproliferative mass without SCC from the cryopreserved specimen. No difference in growth rate was seen. No difference between histologic parameters was seen between the two approaches.

conclusionsFresh human cancer tissue can be immediately cryopreserved and later thawed and implanted to establish PDXs. This resource saving approach allows for tumor profiling prior to implantation into animals thus maximizing the probability that the tumor will be utilized for future research.

Indexed as

Head and Neck NeoplasmsAnimalsCryopreservationDisease Models, AnimalHeterograftsHumansXenograft Model Antitumor AssaysBiobankingCryopreservationPatient-derived xenografts

Identifiers

PMID33910584
PMCPMC8082827
OpenAlexW3158197863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.